Coronavirus Infection Clinical Trial
— HOME-CoVOfficial title:
HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study
Verified date | April 2020 |
Source | University Hospital, Angers |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
COVID-19 pandemic has developed worldwide in less than 4 months. The clinical presentations
are variable widely, ranging from simple rhinitis to major lung damage that can lead to
death.
In many countries involved in the ongoing health disaster due to SARS-CoV-2 infection,
hospital are overloaded. In this context, the decision to hospitalize or to manage COVID-19
patients at home is crucial and defining reliable and consensual criteria is a major issue.
HOME-CoV study is a multicentre quasi-experimental interventional study, before and after
implementation of a help-decision making rule (HOME-CoV rule), developed via the Delphi
method.
Our main hypothesis is that a strategy based on the consensual HOME-CoV rule compared to
current practice is at least as safe as regards the 7-day-rate of adverse events (safety
criterion) and more effective as regards the rate of patients eventually managed as
outpatients (efficacy criterion).
Status | Completed |
Enrollment | 3133 |
Est. completion date | June 17, 2020 |
Est. primary completion date | June 17, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult patient (= 18 years old) - Admitted for COVID-19 infection confirmed by a positive SARS-CoV2 RT-PCR or considered probable by the physician in charge of the patient. - Not requiring care in intensive care unit or resuscitation unit or - No subject of a limitation decision of active therapies, - Free informed express consent to participate in the study orally given or signed by the patient according to local legislation, - Insurance cover according to local legislation; Exclusion Criteria: - Patient whose main diagnostic hypothesis in the emergency room is not a SARS-CoV-2 infection but another differential diagnosis, - Patient admitted to the emergency room for 18 hours or more, - Patient whose follow-up on D28 is impossible, whatever the reason, - Patient with a poor understanding of the French language, - Patient already included in the study, - Person deprived of their liberty by judicial or administrative decision, - Person under psychiatric care under duress, - Person subject to a legal protection measure, - Person unable to express consent. |
Country | Name | City | State |
---|---|---|---|
Belgium | Clinique Universitaire Saint-Luc | Bruxelles | |
Belgium | CHU de Liège | Liege | |
France | Ch Argenteuil | Argenteuil | |
France | CH Cholet | Cholet | |
France | CHU Clermont Ferrand | Clermont Ferrand | |
France | Ch Colmar | Colmar | |
France | CH Alpes Lemant | Contamine-sur-Arve | |
France | CHU Dijon | Dijon | |
France | CH Le Mans | Le Mans | |
France | CH Libourne | Libourne | |
France | CH Limoges | Limoges | |
France | Ch Longjumeau | Longjumeau | |
France | Chu Montpellier | Montpellier | |
France | Centre Hospitalier Universitaire de Nantes | Nantes | |
France | CH Niort | Niort | |
France | Hôpital Bichat | Paris | |
France | Hôpital Lariboisière | Paris | |
France | Hopital Paris Saint Joseph | Paris | |
France | Hopital Saint Antoine | Paris | |
France | CHU de Poitiers | Poitiers | |
France | CH Reims | Reims | |
France | Ch Remiremont | Remiremont | |
France | Chu Rennes | Rennes | |
France | CHU de Rouen | Rouen | |
France | CHU de St Etienne | Saint Etienne | |
France | CH de Saint-Brieuc | Saint-Brieuc | |
France | Ch Troyes | Troyes | |
France | CH VICHY | Vichy | |
Monaco | CH Princesse Grace | Monaco |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Angers |
Belgium, France, Monaco,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the composite rate of adverse outcomes | Adverse outcomes include intubation with mechanical ventilation requirement and death (Stage = 6 on "Ordinal Scale for Clinical Improvement" of the World Health Organization) within 7 days after inclusion. | day 7 | |
Primary | The rate of hospitalization | The rate of patients hospitalized after admission to the emergency room including patients discharged home more than 24 hours after admission. It will be analyzed in a hierarchical approach, only if first primary objective is positive i.e. non-inferiority of HOME-CoV strategy versus current practice on the rate of adverse outcomes. |
24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04369456 -
Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients
|
N/A | |
Completed |
NCT04527471 -
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
|
Phase 2 | |
Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04383899 -
Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
|
||
Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Terminated |
NCT04954014 -
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
|
Phase 2 | |
Completed |
NCT04532632 -
Taste and Smell Impairment in Critically Ill COVID-19 Patients
|
||
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04413435 -
Clinical Characteristics of Critically Ill Patients With COVID-19
|
||
Terminated |
NCT05593770 -
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
|
Phase 2/Phase 3 | |
Completed |
NCT04510493 -
Canakinumab in Patients With COVID-19 and Type 2 Diabetes
|
Phase 3 | |
Active, not recruiting |
NCT04587219 -
The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older
|
Phase 2 | |
Withdrawn |
NCT05430958 -
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04596579 -
SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
|
||
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Terminated |
NCT04442230 -
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 |